… metastasis (BM) in EGFR mutated NSCLC patients. However, whether the combination of
EGFR-TKIs and brain RT is better than EGFR-TKIs … of adding brain RT to EGFR-TKIs and to …

… brain metastases and upfront epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)…
patients treated with upfront local therapy for brain metastases and upfront EGFR-TKI. …

… metastases.19, 20, 21 Nevertheless, in a large, retrospective study of patients with EGFR-…
shorter in patients receiving EGFR TKI therapy alone versus TKI therapy plus upfront WBRT …

… EGFR (8%) or WT (4%) EGFR TKI use was associated with … patients with brain metastases
harboring either EGFR and … was found with regards to intracranial PFS. The results of our …

… of advanced EGFR-mutant NSCLS with brain metastases … EGFR-TKIs and WBRT vs
EGFR-TKI alone in a retrospective cohort of advanced EGFR-mutant NSCLS with brain metastases. …

… OS was generally measured from the start of EGFR TKI therapy or the date of BM diagnosis
… the start of EGFR TKI therapy or the date of BM diagnosis until intracranial progression or the …

… The first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) have … (EGFR)
tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases …

… score, EGFR mutation type, number of BMs and the presence of extracranial metastasis were
… In conclusion, EGFR TKIs have a significant effect on patients with EGFR-mutant BM, and …

… EGFR wild type NSCLC. A growing number of studies focused on the relevance between
EGFR mutation status and brain metastases (BM… six studies without EGFR-TKI treatment before …

… -mutant NSCLCs with central nervous system (CNS) metastases and the role of radiotherapy
… EGFR-TKIs in patients with EGFR-mutant NSCLC with newly diagnosed brain metastases. …